CytomX Therapeutics, Inc. (NASDAQ:CTMX) CFO Debanjan Ray sold 2,500 shares of the stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $21.11, for a total transaction of $52,775.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Debanjan Ray also recently made the following trade(s):
- On Friday, December 1st, Debanjan Ray sold 2,500 shares of CytomX Therapeutics stock. The shares were sold at an average price of $20.58, for a total transaction of $51,450.00.
- On Wednesday, November 1st, Debanjan Ray sold 2,500 shares of CytomX Therapeutics stock. The shares were sold at an average price of $20.00, for a total transaction of $50,000.00.
CytomX Therapeutics, Inc. (NASDAQ:CTMX) traded up $0.63 during trading hours on Thursday, reaching $22.39. 240,900 shares of the company’s stock traded hands, compared to its average volume of 266,100. CytomX Therapeutics, Inc. has a 52-week low of $10.64 and a 52-week high of $24.67. The stock has a market cap of $886.09 and a P/E ratio of -14.26.
A number of brokerages have recently issued reports on CTMX. Cowen reiterated an “outperform” rating on shares of CytomX Therapeutics in a report on Thursday, October 5th. BidaskClub upgraded shares of CytomX Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, December 15th. ValuEngine downgraded shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Zacks Investment Research upgraded shares of CytomX Therapeutics from a “hold” rating to a “buy” rating and set a $24.00 price target for the company in a report on Monday, October 16th. Finally, Cantor Fitzgerald began coverage on shares of CytomX Therapeutics in a report on Monday, October 23rd. They issued an “overweight” rating and a $35.00 price target for the company. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and eight have assigned a buy rating to the company. CytomX Therapeutics has an average rating of “Hold” and a consensus target price of $31.88.
TRADEMARK VIOLATION WARNING: This report was reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at https://www.chaffeybreeze.com/2018/01/04/cytomx-therapeutics-inc-ctmx-cfo-debanjan-ray-sells-2500-shares.html.
CytomX Therapeutics Company Profile
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.